Phase 4 Peripheral Arterial Disease Trial, Recruiting (NCT06873321)

Phase 4 Peripheral Arterial Disease Trial, Recruiting NCT06873321 Sponsor: Science Valley Research Institute Condition: Peripheral Arterial Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06873321 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Peripheral Arterial Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must be an adult of any age and any gender
You must have a serious condition where blood flow to a limb is severely reduced, and your doctors are planning to treat it with either a procedure to open blocked vessels or bypass surgery at a specific hospital in Brazil (HC/EBSERH - UFPE)
You must be willing and able to sign a consent form agreeing to take part in the study

Who may not be able to join:

You may not be able to join if you develop a blood clot in a vein (such as a deep vein clot or a clot in the lungs) during your hospital stay, as this would require a different type of blood-thinning treatment
You may not be able to join if you have any medical reason why you cannot take the medication Rivaroxaban (a blood-thinning drug) — confirm with trial site if you are unsure whether this applies to you
You may not be able to join if you are unable or unlikely to attend a follow-up appointment 30 days after your surgery

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Eduardo Ramacciotti, MD, Ph.D., Science Valley

Phone: +5581991121872

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06873321

Sponsor: Science Valley Research Institute

Phase: Phase 4

Status: Recruiting

Condition: Peripheral Arterial Disease

Trial contact: +5581991121872

More information: https://clinicaltrials.gov/study/NCT06873321

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must be an adult of any age and any gender
You must have a serious condition where blood flow to a limb is severely reduced, and your doctors are planning to treat it with either a procedure to open blocked vessels or bypass surgery at a specific hospital in Brazil (HC/EBSERH - UFPE)
You must be willing and able to sign a consent form agreeing to take part in the study

Who may not be able to join:

You may not be able to join if you develop a blood clot in a vein (such as a deep vein clot or a clot in the lungs) during your hospital stay, as this would require a different type of blood-thinning treatment
You may not be able to join if you have any medical reason why you cannot take the medication Rivaroxaban (a blood-thinning drug) — confirm with trial site if you are unsure whether this applies to you
You may not be able to join if you are unable or unlikely to attend a follow-up appointment 30 days after your surgery

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 4

Sponsor

Science Valley Research Institute

Registry

ClinicalTrials.gov

Start date

24 February 2024

Est. completion

20 July 2025

Where this trial is recruiting

🇧🇷 Brazil

Primary endpoints

primary efficacy outcome; primary safety outcome

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov